Rain Therapeutics Inc

-0.82 (-5.62%)
Earnings Announcements

Rain Therapeutics Reports Qtrly Loss Per Share $0.70

Published: 11/10/2021 13:27 GMT
Rain Therapeutics Inc (RAIN) - Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress.
Rain Therapeutics Inc - Qtrly Loss per Share $0.70.
Rain Therapeutics Inc - Expects Its Quarter-end Cash Position to Provide Runway to Continue Advancing Its Research and Development Pipeline and Complete All Three Planned Clinical Trials of Milademetan.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.53

More details on our Analysts Page.